PTGS2 and head and neck cancer: Rofecoxib, a COX-2–specific inhibitor, is known to increase monocyte binding to intracellular adhesion molecule-1 (ICAM-1) with concomitant enhancement of tumor tissue infiltration and restoration of immune function in head and neck cancer patients [17].